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Abstract
Background: Treatment with tamoxifen or chemotherapy reduces the risk of contralateral breast cancer (CBC).
However, it is uncertain how long the protection lasts and whether the protective effect is modified by patient,
tumor, or treatment characteristics.
Methods: The population-based WECARE Study included 1521 cases with CBC and 2212 age- and year of first
diagnosis-matched controls with unilateral breast cancer recruited during two phases in the USA, Canada, and
Denmark. Women were diagnosed with a first breast cancer before age 55 years during 1985–2008. Abstraction of
medical records provided detailed treatment information, while information on risk factors was obtained during
telephone interviews. Risk ratios (RRs) and 95 % confidence intervals (CIs) for CBC were obtained from multivariable
conditional logistic regression models.
Results: Compared with never users of tamoxifen, the RR of CBC was lower for current users of tamoxifen (RR = 0.73;
95 % CI = 0.55–0.97) and for past users within 3 years of last use (RR = 0.73; 95 % CI = 0.53–1.00). There was no evidence
of an increased risk of estrogen receptor-negative CBC associated with ever use of tamoxifen or use for 4.5 or more
years. Use of chemotherapy (ever versus never use) was associated with a significantly reduced RR of developing
CBC 1–4 years (RR = 0.59; 95 % CI = 0.45–0.77) and 5–9 years (RR = 0.73; 95 % CI = 0.56–0.95) after first breast cancer
diagnosis. RRs of CBC associated with tamoxifen or with chemotherapy use were independent of age, family history of
breast cancer, body mass index and tumor characteristics of the first breast cancer with the exception that the RR of
CBC was lower for lobular histology compared with other histologies.
Conclusion: Our findings are consistent with previous studies showing that treatment with tamoxifen or chemotherapy
is associated with a lower risk of CBC although the risk reduction appears to last for a limited time period after
treatment is completed.
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Background
Women who receive tamoxifen or chemotherapy as
treatment for breast cancer are at reduced risk of devel-
oping contralateral breast cancer (CBC) according to
findings from randomized trials [1, 2] and observational
studies [3–9]. Nonetheless, several unresolved questions
regarding these associations remain.
Data on how long the protective effect persists are
sparse in relation to tamoxifen [2, 6, 9] and chemo-
therapy [6]; however, prior studies suggest that the risk
reduction may last for up to 10 years following first
breast cancer diagnosis. For tamoxifen, the first phase of
the WECARE (Women’s Environmental, Cancer, and
Radiation Epidemiology) Study showed a risk increase
beyond 10 years after first breast cancer diagnosis [6].
Duration of tamoxifen treatment may influence the effi-
cacy over time, during periods of active treatment, and
afterwards, but this is also understudied [3, 9, 10]. The
Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG) Study published in 2011 demonstrated a pro-
tective effect lasting for up to 5 years after ending 5 years
of tamoxifen treatment [2]. Regarding risk of estrogen
receptor (ER)-specific CBC, one study nested within a
registry-based cohort of women with ER-positive breast
cancer showed that duration of tamoxifen treatment for
5 or more years was associated with an increased risk of
ER-negative second tumors [10].
Some evidence indicates that tamoxifen may only
reduce the risk of CBC for women diagnosed with an
ER-positive first tumor [2] and that chemotherapy offers
protection against CBC only for women younger than
50 years at treatment [1]. Both types of systemic therapy
have been shown to be protective against CBC in
BRCA1 and BRCA2 mutation carriers [11–13]. It is un-
clear whether other characteristics, such as body mass
index (BMI), influence the risk of CBC associated with
systemic breast cancer therapy.
A better understanding of these issues is critical since
CBC is a major concern for breast cancer survivors.
Therefore, we analyzed data from the expanded WECARE
Study, a large international population-based case-control




Recruitment and data collection for the WECARE Study
were conducted in two phases, herein referred to as
WECARE I (2001–2004) and WECARE II (2009–2012).
All participants were identified through eight population-
based cancer registries: six in the USA, one in Canada and
one in Denmark (Table 1). Selected from a large cohort of
women diagnosed with an invasive breast cancer, case
patients were diagnosed with CBC and control patients
were diagnosed with unilateral breast cancer.
Cases and controls in WECARE I and II were eligible
for inclusion if the first breast cancer was invasive with no
disease spread beyond regional lymph nodes and diag-
nosed during 1985–2008 before age 55 years. Cases were
diagnosed with CBC during 1986–2011, and the interval
between the first and second diagnoses was at least 1 year
in WECARE I and 2 years in WECARE II. Invasive and
in-situ CBCs (the latter accounting for 20 % of CBCs)
were eligible for WECARE I, whereas only invasive CBCs
were included in WECARE II. Cases and controls were in-
dividually matched in triplets (one case and two controls)
in WECARE I and in pairs in WECARE II by age at first
breast cancer (5-year strata), calendar-year of first diagno-
sis (4-year strata), cancer registry, and race/ethnicity. In
WECARE I, for statistical purposes, cases and controls
were further counter-matched on radiotherapy so that in
each triplet two women had received radiotherapy and
one woman had not. The reference date for cases was the
CBC diagnosis date while for controls it was defined by
adding the interval between the first breast cancer and
CBC for the matched case to the date of unilateral breast
cancer for the control. No other cancer diagnoses, except
non-melanoma skin cancer, were allowed up to and in-
cluding the reference date. The ‘at-risk’ period was defined
as beginning at the date of first cancer diagnosis and end-
ing at the reference date. During this period cases and
controls had to reside within the same registry catchment
area. Controls were ineligible if they had a prophylactic
contralateral mastectomy before the reference date.
All participants had to be alive at the time of contact
in order to complete a telephone interview and pro-
vide a biospecimen.
Data collection
Information regarding treatment for the first breast can-
cer and any recurrences during the ‘at-risk’ period was
obtained by abstracting medical records. The recorded
information on chemotherapy and hormonal therapy in-
cluded start and end dates of administration, reason for
treatment, and type of drug. If treatment information
was unavailable in the medical record, we used self-
reported information (for chemotherapy 4 % and for
tamoxifen 5 % of all patients).
Medical records were used to obtain information on
tumor characteristics (histology, stage, and ER and pro-
gesterone receptor (PR) status) for the first breast cancer
and the CBC. Information on tumor characteristics was
also sought from the cancer registries where available.
The telephone interview included questions on known
breast cancer risk factors.
A total of 2354 cases and 3599 controls were eligible
and invited to participate in the WECARE studies. The
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final number of participants who completed the inter-
view and provided a biospecimen was 1521 (65 %) cases
and 2212 (62 %) controls. All participants gave written
informed consent before enrollment, and the study pro-
tocols were approved by the institutional review boards
at the University of Iowa (IRB-01), Fred Hutchinson
Cancer Research Center, Cancer Prevention Institute of
California, University of Southern California, Beckman
Research Institute of the City of Hope, University of
California at Irvine, Mount Sinai Hospital, Danish Cancer
Society and Memorial Sloan Kettering Cancer Center, and
by the Committee for the Protection of Human Subjects
of the State of California and the ethical committee system
in Denmark.
Statistical methods
We used multivariable-adjusted conditional logistic
regression models to estimate risk ratios (RRs) and 95 %
confidence intervals (CIs) for CBC associated with
systemic therapy used to treat first primary breast can-
cer. We estimated the RR for CBC associated with ever
use of tamoxifen or chemotherapy versus never use as
the reference category. We also calculated RRs associ-
ated with time since first breast cancer diagnosis (1–4,
5–9, ≥10 years), age at first breast cancer diagnosis (≤39,
Table 1 Characteristics of breast cancer patients in the WECARE
I and II Study
Characteristics CBC cases UBC controls
N (%) N (%)
Overall numbers 1521 (100) 2212 (100)
Study area
Iowaa 201(13) 314 (14)
Seattleb 224 (15) 317 (14)
Ontarioc 159 (10) 157 (7)
Californiad 658 (43) 967 (44)
Denmarke 279 (18) 457 (21)
Age at first breast cancer (years)
≤39 268 (18) 384 (17)
40–49 808 (53) 1180 (53)
50–54 445 (29) 648 (29)
Age at CBC/reference date (years)
≤39 100 (6) 147 (7)
40–49 446 (29) 691 (31)
50–59 719 (48) 1087 (49)
≥60 256 (17) 287 (13)
Year of diagnosis of first breast cancer
1985–1989 303 (20) 580 (26)
1990–1994 572 (38) 871 (39)
1995–1999 426 (28) 551 (25)
2000–2004 186 (12) 190 (9)
2005–2008 34 (2) 20 (1)
Time since first breast cancer (years)
1–4 586 (39) 986 (45)
5–9 574 (38) 804 (36)
≥10 361 (24) 422 (19)
First-degree family history of breast cancer
Yes 497 (33) 466 (21)
No 1004 (66) 1706 (77)
Unknown 20 (1) 40 (2)
Lobular histology of first breast cancer
Yes 179 (12) 223 (10)
No 1342 (88) 1989 (90)
Stage of first breast cancer
Local 1061 (70) 1442 (65)
Regional 448 (29) 759 (34)
Unknown 12 (1) 11 (1)
ER/PR status of the first breast cancer
Positive 863 (57) 1379 (62)
Negative 413 (27) 473 (21)
Unknown 245 (16) 360 (16)
Table 1 Characteristics of breast cancer patients in the WECARE
I and II Study (Continued)
Radiation for first breast cancerf
Yes 880 (58) 1686 (76)
No 641 (42) 525 (24)
Chemotherapy for first breast cancer
Yes 822 (54) 1289 (58)
No 699 (46) 923 (42)
Tamoxifen use for first breast cancer
Yes 467 (31) 787 (36)
No 1054 (69) 1425 (64)
Other endocrine therapy for first
breast cancerg
Yes 89 (6) 141 (6)
No 1432 (94) 2071 (94)
aThe State Health Registry of Iowa
bCancer Surveillance System of the Fred Hutchinson Cancer Research Center
cThe Ontario Cancer Registry
dFour study centers: 1) Los Angeles County Cancer Surveillance Program,
2) The Cancer Surveillance Program of Orange County/San Diego-Imperial
Organization for Cancer Control, 3) Greater Bay Area Cancer Registry (San Francisco
Bay Area Region and Santa Clara Region), and 4) Sacramento and Sierra Center
Registry (Sacramento Region)
eThe Danish Breast Cancer Cooperative Group Database supplemented by the
Danish Cancer Registry
fRadiation for first breast cancer was unknown for one control
gAromatase inhibitors (67 cases and 99 controls) and other anti-estrogens
CBC contralateral breast cancer, ER/PR estrogen receptor/progesterone
receptor (if either ER or PR was positive, we considered the ER/PR status as
positive), UBC unilateral breast cancer
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40–49, 50–54 years), year of first breast cancer diagnosis
(1985–1989, 1990–1994, 1995–1999, 2000–2004, 2005–
2008), first-degree family history of breast cancer (yes,
no), BMI (<25, 25–29.9, ≥30 kg/m2), histology (lobular,
other), and ER/PR status (positive, negative). If either ER
or PR was positive, we considered ER/PR status to be
positive. To account for the counter-matching in
WECARE I, we included a log-weight covariate offset
term. For WECARE II participants who were matched
in pairs, we assigned the value of 1 to the offset term.
Analyses of the effects of tamoxifen treatment were
stratified by duration of use (≤18, 19–53, ≥54 months, or
<54, ≥54 months) and by time since last use at reference
date (0 (current use at reference date), >0–37 months
(past use), ≥37 months (past use)). The cut-point at
37 months was the median for values greater than 0 for
controls who received tamoxifen.
We also estimated RRs for ER-positive and ER-
negative CBCs separately for ever versus never use of
tamoxifen and by duration and time since last use at ref-
erence date.
All analyses of associations of risk with tamoxifen
treatment were repeated after restricting eligibility to
women with a hormone receptor-positive first breast
cancer.
For chemotherapy, we examined the association be-
tween different regimens and CBC risk. A woman was
classified as having received a chemotherapeutic regimen
if she received the combination of the drugs for either
her first primary breast cancer or a recurrence (see
Table 5 for regime classifications).
Additionally, we examined the RR of CBC for different
combinations of breast cancer treatment comparing
women to those who only underwent surgery for their
first breast cancer. We also performed sensitivity ana-
lyses excluding either participants diagnosed with in-situ
CBC or participants diagnosed with recurrences during
the ‘at-risk’ period.
Multivariable models were adjusted for age at first
diagnosis, first-degree family history of breast cancer,
histology, stage, and ER/PR status of the first breast can-
cer and radiotherapy. In tamoxifen analyses, we further
adjusted for other endocrine therapy and chemotherapy,
whereas chemotherapy analyses were adjusted for endo-
crine therapy.
Results
The majority of WECARE Study participants were
diagnosed with first primary breast cancer during
1990–1999 (Table 1). Twenty-four percent of cases were
diagnosed with CBC 10 or more years after the first breast
cancer diagnosis. More than half of the participants had a
receptor-positive first breast cancer.
Tamoxifen use during the ‘at-risk’ period was associ-
ated with a statistically significant decreased RR of CBC
(ever versus never use: RR = 0.76; 95 % CI = 0.63–0.92)
(Table 2). Reduced RRs were seen 1–4 years and 5–9
years after the first breast cancer diagnosis, but not after
10 or more years. However, the RRs of CBC did not
differ statistically by time since first breast cancer
diagnosis (P heterogeneity = 0.3) or by duration of use
(overall P value = 0.7). We found a decreased risk of
CBC for current users of tamoxifen (RR = 0.73; 95 %
CI = 0.55–0.97) and for past users who stopped tam-
oxifen treatment within 37 months before the refer-
ence date (RR = 0.73; 95 % CI = 0.53–1.00); for women
who stopped using tamoxifen ≥37 months before the
reference date, CBC risk was close to unity (overall P
value = 0.2). The RR for current users was lower and
only statistically significant for those using tamoxifen
for 54 months or longer (RR = 0.44; 95 % CI = 0.27–
0.73) compared with those with shorter use (RR =
0.86; 95 % CI = 0.62–1.19). Within 37 months of end-
ing therapy, there were no statistically significant re-
ductions in CBC risk for women using tamoxifen for
less than 54 months or for women using tamoxifen
for 54 months or longer.
We found a statistically significant decreased RR of
ER-positive CBC (RR = 0.75; 95 % CI = 0.58–0.96) com-
paring women treated with tamoxifen with those not
receiving tamoxifen treatment (Table 3). The RR of
ER-negative CBC for ever receiving tamoxifen treatment
was close to unity (RR = 0.92; 95 % CI = 0.59–1.44). There
was no increase in the RR of ER-negative CBC for
tamoxifen use for ≥54 months either overall (RR = 0.93;
95 % CI = 0.50–1.74) or when restricting to current users
(RR = 0.76; 95 % CI = 0.25–2.37).
No statistically significant differences in associations
with CBC risk were observed for tamoxifen use by age at
first breast cancer or year at first breast cancer, family his-
tory of breast cancer, BMI or ER/PR status of first breast
cancer (P heterogeneity = 0.1–0.9) (Table 4). Tamoxifen
users with a lobular histology of their first tumor had a
more pronounced reduction in CBC risk than users with
other types of tumors (P heterogeneity = 0.03).
Results for women with hormone receptor-positive
first tumors (Additional file 1: Tables S1–S4) were simi-
lar to the findings for tamoxifen and CBC risk for all
participants, although for the former group a RR of 1.61
(95 % CI = 0.92–2.79) (Additional file 1: Table S2) was
found versus a RR of 1.25 (95 % CI = 0.84–1.86) for the
latter group (Table 2) for ≥54 months of tamoxifen use
ending ≥37 months before the reference date. For ER-
positive CBC, RRs of 1.59 (95 % CI = 0.94–2.68) (Add-
itional file 1: Table S3) and 1.07 (95 % CI = 0.74–1.56)
(Table 3), respectively, were found for these groups if
ending treatment ≥37 months before reference date.
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Table 2 Risk ratios of contralateral breast cancer associated with different aspects of tamoxifen use
Use of tamoxifen CBC cases UBC controls RRa (95 % CI) P value P het.
N (%) N (%)
Tamoxifen use
Never 1054 (69) 1425 (64) 1.0 (Referent)
Ever 467 (31) 787 (36) 0.76 (0.63–0.92)
Tamoxifen use according to time since first breast cancer
1–4 years
Never 423 (72) 644 (65) 1.0 (Referent)
Ever 163 (28) 342 (35) 0.67 (0.51–0.88)
5–9 years
Never 387 (67) 504 (63) 1.0 (Referent)
Ever 187 (33) 300 (37) 0.76 (0.57–1.03) 0.3
≥10 years
Never 244 (68) 277 (66) 1.0 (Referent)
Ever 117 (32) 145 (34) 0.95 (0.67–1.34)
Mean duration of tamoxifen (months) 40.2 40.5 0.8
Median duration of tamoxifen (months) 44 43 0.6
Interquartile range (months) 20–60 18–60
Range (months) >0–106 >0–174
Duration of tamoxifen use
Never 1054 (69) 1425 (64) 1.0 (Referent)
≤18 months 92 (6) 165 (7) 0.90 (0.65–1.24)
19–53 months 139 (9) 242 (11) 0.76 (0.57–1.00) 0.7e
≥54 months 167 (11) 244 (11) 0.80 (0.61–1.04)
Unknownb 69 (5) 136 (6)
Mean time since last use at reference date for past users (months) 57.1 45.2 0.0001
Median time since last use at reference date for past users (months) 48 37 0.0001
Interquartile range (months) 24–83 13–65
Range (months) 1–204 1–186
Time since last tamoxifen use at reference datec
Never 1054 (69) 1425 (64) 1.0 (Referent)
Current use, 0 months since last used 131 (9) 249 (11) 0.73 (0.55–0.97)
Past use, <37 months since last use 110 (7) 206 (9) 0.73 (0.53–1.00) 0.2e
Past use, ≥37 months since last use 161 (11) 208 (9) 0.98 (0.73–1.31)
Unknownb 65 (4) 124 (6)
Time since last tamoxifen use at reference date according to duration of use
Never 1054 (69) 1425 (64) 1.0 (Referent)
<54 months duration
Current used 101 (7) 178 (8) 0.86 (0.62–1.19)
Past use, <37 months since last use 53 (3) 112 (5) 0.71 (0.47–1.07)
Past use, ≥37 months since last use 77 (5) 117 (5) 0.82 (0.56–1.19)
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Use of chemotherapy during the ‘at-risk’ period versus
no chemotherapy was associated with a reduced risk of
CBC (RR = 0.71; 95 % CI = 0.59–0.85) (Table 5). We found
statistically significant decreased RRs of CBC associated
with chemotherapy 1–4 years (RR = 0.59; 95 % CI = 0.45–
0.77) and 5–9 years (RR = 0.73; 95 % CI = 0.56–0.95) after
first diagnosis, whereas no association was found ≥10 years
after first diagnosis. There were no statistically significant
associations with receipt of chemotherapy by age at first
breast cancer or year at first breast cancer, family history
of breast cancer, BMI, histology, or ER/PR status of first
breast cancer (P heterogeneity = 0.07–0.8). We found the
largest risk reductions for cyclophosphamide, methotrex-
ate, and fluorouracil (CMF) regimens (RR = 0.67; 95 %
CI = 0.54–0.83) and other regimens (RR = 0.55; 95 %
CI = 0.31–0.97) (overall P value = 0.003) (Table 6).
We found a reduced risk of CBC for women who were
treated with chemotherapy only compared with women
who had undergone surgery only (RR = 0.68; 95 % CI =
0.49–0.93), whereas no association was observed for
tamoxifen only (RR = 1.06; 95 % CI = 0.69–1.64)
(Table 7). The largest decrease in CBC risk was associ-
ated with concurrent administration of chemotherapy,
tamoxifen and radiotherapy (RR = 0.54; 95 % CI = 0.39–
0.76) and non-tamoxifen endocrine therapy used with or
without other therapies (RR = 0.49; 95 % CI = 0.33–0.72).
Sensitivity analyses excluding cases diagnosed with in-
situ CBC or participants diagnosed with recurrences
showed no major changes in RR estimates (results not
shown).
Discussion
In the WECARE Study, we showed that reduction in CBC
risk was associated with longer duration of tamoxifen use
for current users and it continued up to 3 years after end-
ing treatment for past users. There was no increase in risk
of ER-negative CBC associated with tamoxifen use for
≥54 months. A CBC risk reduction for up to 10 years after
the first breast cancer diagnosis was found for women
treated with chemotherapy. We found no evidence that
CBC risks associated with these systemic treatments dif-
fered by age, year of diagnosis, family history of breast
cancer, BMI, or ER/PR status, but the association with
tamoxifen differed by histology of the first cancer.
In the meta-analysis by the EBCTCG published in 1998,
comparing breast cancer clinical trials with different dura-
tions of tamoxifen use, reductions in CBC risk were larger
in trials of 5 years of tamoxifen use versus those of 1 or
2 years of use [14]. A review published in 1999 of 18 up-
dated trials revealed comparable results [15]. Two case-
control studies reported no clear difference in CBC risk by
duration of tamoxifen use, although the reduction in CBC
risk was only statistically significant when tamoxifen was
used for more than 1 year [3, 10]. One previous cohort
study examined duration of use for current users and
found similar results [9]. Our finding, that current users of
tamoxifen with longer durations of use tend to have the
largest CBC risk reduction, is consistent with longer treat-
ment having a greater impact on risk. Thus, the recent
recommendations that tamoxifen should be used for
10 years [16] may also be beneficial in respect to CBC risk.
An important question concerns the length of the pro-
tection against CBC after discontinuation of tamoxifen.
The latest EBCTCG meta-analysis from 2011 showed a
CBC risk reduction up to 5–9 years after the first breast
cancer diagnosis corresponding to 0–4 years after ending
treatment in trials testing 5 years of tamoxifen versus no
tamoxifen [2]. One previous observational study [3]
reported an odds ratio of 0.4 up to 1 year after treatment
cessation, but no risk reduction was seen more than 1 year
after ending treatment. The reduction in CBC risk in our
study continued for 3 years after completion of treatment.
This finding is consistent with a preventive effect of
tamoxifen on CBC lasting for a limited time period after
ending the treatment. This is in contrast to the most re-
cent prevention trial showing that high-risk women
treated with tamoxifen for 5 years continue to have a de-
creased risk of developing breast cancer throughout the
available follow-up of a median of 16.0 years from
randomization [17].
Table 2 Risk ratios of contralateral breast cancer associated with different aspects of tamoxifen use (Continued)
≥54 months duration 0.01e
Current used 28 (2) 69 (3) 0.44 (0.27–0.73)
Past use, <37 months since last use 56 (4) 90 (4) 0.71 (0.45–1.12)
Past use, ≥37 months since last use 83 (5) 85 (4) 1.25 (0.84–1.86)
Unknown durationb 69 (5) 136 (6)
aAdjusted for age at first breast cancer diagnosis (continuous), first-degree family history of breast cancer (yes, no, unknown), histology (lobular, other, unknown),
stage (local, regional, unknown), and estrogen receptor/progesterone receptor status (positive for either, negative, unknown) at first diagnosis, radiation (yes, no),
chemotherapy (yes, no), and other endocrine therapy (yes, no)
bUnknown not included in model
cCut-point at median for values greater than 0 months in WECARE I and II controls
dCurrent users of tamoxifen at reference date
eOverall P-value
CBC contralateral breast cancer, CI confidence intervals, P-het. P value for heterogeneity, RR risk ratio, UBC unilateral breast cancer
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Although the latest meta-analyses by the EBCTCG
showed the preventive effect of tamoxifen on the devel-
opment of CBC was limited to women with an ER-
positive first breast cancer [2], trials initiated before 1990
showed similar CBC risk reductions for patients with ER-
poor tumors as for other patients [14]. Similarly, our
Table 3 Risk ratios of ER-positive and ER-negative contralateral breast cancer associated with different aspects of tamoxifen use
Use of tamoxifen CBC cases UBC controls RRa (95 % CI) P value
N (%) N (%)
ER-positive CBCb
Never 525 (63) 692 (62) 1.0 (referent)
Ever 303 (37) 421 (38) 0.75 (0.58–0.96)
Duration of tamoxifen use
Never 525 (63) 692 (62) 1.0 (referent)
<54 months 142 (17) 198 (18) 0.84 (0.61–1.15)
≥54 months 117 (14) 149 (13) 0.80 (0.57–1.12)
Unknownc 44 (5) 74 (7)
Test for trend 0.2
Overall P value 0.3
Time since last use at reference date
Never 525 (63) 692 (62) 1.0 (referent)
Current use, duration <54 months 56 (7) 83 (7) 0.82 (0.52–1.30)
Current use, duration ≥54 months 20 (2) 41 (4) 0.38 (0.20–0.72)
Past use, <37 months since last use 68 (8) 97 (9) 0.72 (0.47–1.12)
Past use, ≥37 months since last use 116 (14) 131 (12) 1.07 (0.74–1.56)
Unknownc 43 (5) 69 (6)
Overall P value 0.02
ER-negative CBCb
Never 282 (78) 318 (64) 1.0 (referent)
Ever 79 (22) 180 (36) 0.92 (0.59–1.44)
Duration of tamoxifen use
Never 282 (78) 318 (64) 1.0 (referent)
<54 months 39 (11) 87 (17) 1.03 (0.58–1.82)
≥54 months 29 (8) 58 (12) 0.93 (0.50–1.74)
Unknownc 11 (3) 35 (7)
Test for trend 0.9
Overall P value 1.0
Time since last use at reference date
Never 282 (78) 318 (64) 1.0 (referent)
Current use, duration <54 months 18 (5) 35 (7) 1.54 (0.68–3.47)
Current use, duration ≥54 months 5 (1) 14 (3) 0.76 (0.25–2.37)
Past use, <37 months since last use 21 (6) 45 (9) 1.12 (0.55–2.27)
Past use, ≥37 months since last use 25 (7) 55 (11) 0.66 (0.31–1.42)
Unknownc 10 (3) 31 (6)
Overall P value 0.6
CBC contralateral breast cancer, CI confidence intervals, ER estrogen receptor, RR risk ratio, UBC unilateral breast cancer
aAdjusted for age at first breast cancer diagnosis (continuous), first-degree family history of breast cancer (yes, no, unknown), histology (lobular, other, unknown),
stage (local, regional, unknown) and ER/progesterone receptor status (positive for either, negative, unknown) at first diagnosis, radiation (yes, no), chemotherapy
(yes, no), and other endocrine therapy (yes, no)
bThese models are subset models (two separate models for ER-positive CBC and ER-negative CBC). ER status for CBC was missing for 332 cases
cUnknown not included in model
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results show that treatment with tamoxifen is associated
with reduced risk for patients with hormone receptor-
positive and for patients with receptor-negative first breast
cancers. This would be compatible with CBCs represent-
ing a second independent tumor and not recurrent or
metastatic disease [18]. A concern has been raised in two
studies by Li et al. [10, 19] showing that tamoxifen may in-
crease the risk of ER-negative CBC. The first was a cohort
study based on SEER data from western Washington [19],
while the second was a nested case-control study within
the same study population, although updated with an ex-
tended range of diagnosis years, restriction to ER-positive
first primary cases, and detailed medical record reviews
[10]. The latter study showed that the excess of ER-
negative CBC was confined to patients with >5 years of
tamoxifen use [10]. Reassuringly, we and a recent cohort
study from Geneva [20] were not able to confirm these
observations.
Consistent with previous studies, we found that CBC
risk associated with tamoxifen did not differ by age [2, 14]
Table 4 Risk ratios of contralateral breast cancer associated with tamoxifen use by patient and tumor characteristics
No tamoxifen Tamoxifen
CBC cases UBC controls RR CBC cases UBC controls RRa (95 % CI) P het.
N (%) N (%) N (%) N (%)
Age at 1st breast cancer (years)b
≤39 222 (83) 293 (76) 1.0 46 (17) 91 (24) 0.69 (0.43–1.10)
40–49 559 (69) 782 (66) 1.0 249 (31) 398 (34) 0.79 (0.62–1.01) 0.9
50–54 273 (61) 350 (54) 1.0 172 (39) 298 (46) 0.75 (0.56–1.00)
Year of diagnosis of first breast cancer
1985–1989 250 (83) 472 (81) 1.0 53 (17) 108 (19) 1.18 (0.75–1.87)
1990–1994 400 (70) 564 (65) 1.0 172 (30) 307 (35) 0.86 (0.65–1.13)
1995–1999 280 (66) 306 (56) 1.0 146 (34) 245 (44) 0.65 (0.48–0.88) 0.1
2000–2004 101 (54) 71 (37) 1.0 85 (46) 119 (63) 0.52 (0.32–0.85)
2005–2008 23 (68) 12 (60) 1.0 11 (32) 8 (40) 0.88 (0.26–2.92)
First-degree family history of breast cancerc
Yes 344 (69) 298 (63) 1.0 154 (31) 172 (37) 0.82 (0.60–1-12)
No 703 (70) 1115 (65) 1.0 307 (30) 602 (35) 0.76 (0.62–0.94) 0.7
Unknownd 7 (54) 12 (48) 1.0 6 (46) 13 (52)
BMI at 1st breast cancer (kg/m2)
<25 749 (71) 991 (66) 1.0 303 (29) 506 (34) 0.76 (0.61–0.95)
25–29.9 191 (64) 307 (62) 1.0 108 (36) 189 (38) 0.81 (0.57–1.15) 0.9
≥30 111 (67) 124 (58) 1.0 55 (33) 91 (42) 0.71 (0.44–1.14)
Unknownd 3 (75) 3 (75) 1.0 1 (25) 1 (25)
Histology of first breast cancere
Lobular 112 (63) 103 (46) 1.0 67 (37) 120 (54) 0.48 (0.31–0.75) 0.03
Other 940 (70) 1,321 (67) 1.0 398 (30) 665 (33) 0.82 (0.67–0.99)
Unknownd 2 (50) 1 (33) 2 (50) 2 (67)
ER/PR status of first breast cancerf
Positive 450 (52) 679 (49) 1.0 413 (48) 700 (51) 0.75 (0.60–0.93)
Negative 388 (94) 422 (89) 1.0 25 (6) 51 (11) 0.54 (0.30–0.98) 0.3
Unknownd 216 (88) 324 (90) 1.0 29 (12) 36 (10)
aAdjusted for age at first breast cancer diagnosis (continuous), first-degree family history of breast cancer (yes, no, unknown), histology (lobular, other, unknown),
stage (local, regional, unknown) and ER/PR status (positive for either, negative, unknown) at first diagnosis, radiation (yes, no), chemotherapy (yes, no), and other
endocrine therapy (yes, no)
bRR are adjusted for all variables listed in footnote “a”, except age at first breast cancer diagnosis
cRR are adjusted for all variables listed in footnote “a”, except first-degree family history of breast cancer
dUnknown not included in model
eRR are adjusted for all variables listed in footnote “a”, except histology of first breast cancer diagnosis
fRR are adjusted for all variables listed in footnote “a”, except ER/PR status of first breast cancer diagnosis
BMI body mass index, CBC contralateral breast cancer, CI confidence interval, ER/PR estrogen receptor/progesterone receptor, P het; P value for heterogeneity, RR
risk ratio, UBC unilateral breast cancer
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or BMI [21]. Studies have shown that tamoxifen might
also be effective in BRCA1 and BRCA2 mutation carriers
in respect to reducing CBC risk [11] consistent with our
finding of risk reductions regardless of family history of
breast cancer. However, due to the higher baseline rate of
CBC for breast cancer patients with family history com-
pared with those with no family history, the absolute
numbers prevented would be larger in the former group.
Table 5 Risk ratios of contralateral breast cancer associated with chemotherapy by time, patient, and tumor characteristics
No chemotherapy Chemotherapy
CBC cases UBC controls RR CBC cases UBC controls RRa (95 % CI) P het.
N (%) N (%) N (%) N (%)
Ever use of chemotherapy (yes/no) 699 (46) 923 (42) 1.0 822 (54) 1,289 (58) 0.71 (0.59–0.85)
Time since first breast cancer (years)
1–4 278 (47) 402 (41) 1.0 308 (53) 584 (59) 0.59 (0.45–0.77)
5–9 249 (43) 322 (40) 1.0 325 (57) 482 (60) 0.73 (0.56–0.95) 0.1
≥10 172 (48) 199 (47) 1.0 189 (52) 223 (53) 0.92 (0.65–1.30)
Age at 1st breast cancer (years)b
≤39 59 (22) 88 (23) 1.0 209 (78) 296 (77) 0.99 (0.63–1.57)
40–49 372 (46) 469 (40) 1.0 436 (54) 711 (60) 0.65 (0.52–0.82) 0.2
50–54 268 (60) 366 (56) 1.0 177 (40) 282 (44) 0.70 (0.52–0.94)
Year of diagnosis of first breast cancer
1985–1989 192 (63) 295 (51) 1.0 111 (37) 285 (49) 0.66 (0.46–0.95)
1990–1994 283 (49) 392 (45) 1.0 289 (51) 479 (55) 0.71 (0.55–0.92)
1995–1999 157 (37) 190 (34) 1.0 269 (63) 361 (66) 0.79 (0.58–1.08) 0.5
2000–2004 58 (31) 40 (21) 1.0 128 (69) 150 (79) 0.47 (0.27–0.83)
2005–2008 9 (26) 6 (30) 1.0 25 (74) 14 (70) 1.17 (0.31–4.43)
First-degree family history of breast cancerc
Yes 219 (44) 211 (45) 1.0 279 (56) 259 (55) 0.89 (0.65–1.20)
No 474 (47) 704 (41) 1.0 536 (53) 1,013 (59) 0.65 (0.53–0.80) 0.07
Unknownd 6 (46) 8 (32) 1.0 7 (54) 17 (68)
BMI at first breast cancer (kg/m2)
<25 538 (51) 660 (44) 1.0 514 (49) 837 (56) 0.66 (0.53-0.81)
25–29.9 107 (36) 192 (39) 1.0 192 (64) 304 (61) 0.83 (0.59-1.18) 0.3
≥30 52 (31) 68 (32) 1.0 114 (69) 147 (68) 0.89 (0.55-1.44)
Unknownd 2 (50) 3 (75) 1.0 2 (50) 1 (25)
Histology of first breast cancere
Lobular 86 (48) 94 (42) 1.0 93 (52) 129 (58) 0.77 (0.49–1.21)
Other 610 (46) 828 (42) 1.0 728 (54) 1,158 (58) 0.70 (0.58–0.85) 0.7
Unknownd 3 (75) 1 (33) 1 (25) 2 (67)
ER/PR status of first breast cancerf
Positive 419 (49) 609 (44) 1.0 444 (51) 770 (56) 0.72 (0.57–0.91)
Negative 91 (22) 96 (20) 1.0 322 (78) 377 (80) 0.67 (0.45–1.02) 0.8
Unknownd 189 (77) 218 (61) 1.0 56 (23) 142 (39)
aAdjusted for age at first breast cancer diagnosis (continuous), first-degree family history of breast cancer (yes, no, unknown), histology (lobular, other, unknown),
stage (local, regional, unknown) and ER/PR status (positive for either, negative, unknown) at first breast cancer diagnosis, radiation therapy (yes, no), and endocrine
therapy (yes, no)
bRR are adjusted for all variables listed in footnote “a”, except age at first breast cancer diagnosis
cRR are adjusted for all variables listed in footnote “a”, except first-degree family history of breast cancer
dUnknown not included in model
eRR are adjusted for all variables listed in footnote “a”, except histology of first breast cancer diagnosis
fRR are adjusted for all variables listed in footnote “a”, except ER/PR status of first breast cancer diagnosis
BMI body mass index, CBC contralateral breast cancer, CI confidence interval, ER/PR estrogen receptor/progesterone receptor, P het; P value for heterogeneity, RR
risk ratio, UBC unilateral breast cancer
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To our knowledge, no previous studies have investigated
whether associations differed by histologic subtype. There-
fore, the finding of a lower CBC risk after tamoxifen use
for patients with lobular first breast cancer compared with
other types is novel.
Little is known about how chemotherapy affects risk
of CBC over time. Some studies failed to show risks
deviating from unity during both short- and long-term
time intervals after first breast cancer [5, 22]. A study
from the Netherlands reported an overall reduction in
CBC after chemotherapy; however, for 5-year survivors
followed up to 15 years, no significant risk reduction
was seen [4]. Our study suggests that the protective
effect of chemotherapy on CBC persists for up to
10 years after the first breast cancer diagnosis.
In the 2005 EBCTCG meta-analysis, the beneficial
effects of chemotherapy on CBC were restricted to
younger women [1]. We were able to confirm this find-
ing in the WECARE Study as all our participants were
younger than 55 years at first breast cancer diagnosis;
however, we found no tendency towards a lower risk by
decreasing age. Also, in the 2005 EBCTCG study, a sig-
nificant reduction in CBC risk was observed for women
below age 50 years treated with CMF regimens but not
with anthracycline regimens [1]. In the latest EBCTCG
update from 2012, no significant effect of either
Table 6 Risk ratios of contralateral breast cancer associated with chemotherapy regimen
Chemotherapeutic regimenb CBC cases UBC controls
N (%) N (%) RRa (95 % CI) Overall P value
No chemotherapy 699 (46) 923 (42) 1.00 (Referent)
Taxanes ± any other chemotherapeuticsc 105 (7) 113 (5) 0.84 (0.57–1.24)
Anthracycline-based regimensd 291 (19) 381 (17) 0.80 (0.62–1.04) 0.003
CMFe 321 (21) 629 (28) 0.67 (0.54–0.83)
Other regimensf 25 (2) 55 (2) 0.55 (0.31–0.97)
Unknowng 80 (5) 111 (5)
aAdjusted for age at first breast cancer diagnosis (continuous), first-degree family history of breast cancer (yes, no, unknown), histology (lobular, other, unknown),
stage (local, regional, unknown) and estrogen receptor/progesterone receptor status (positive for either, negative, unknown) at first breast cancer diagnosis, radi-
ation therapy (yes, no), and endocrine therapy (yes, no)
bEach regimen adjusted for the other regimens listed here in addition to all variables listed in footnote “a”
cDocetaxel, paclitaxel ± all other chemotherapeutic drugs
dCyclophosphamide, adriamycin and/or epirubicin alone or in combination with fluorouracil and/or methotrexate. No other chemotherapeutic drugs allowed
eCyclophosphamide (C) and/or methotrexate (M) and/or fluorouracil (F). No other chemotherapeutic drugs allowed
fAll other chemotherapeutic drugs and combinations
gUnknown not included in model
CBC contralateral breast cancer, CI confidence interval, RR risk ratio, UBC unilateral breast cancer
Table 7 Risk ratios of contralateral breast cancer associated with different combinations of breast cancer treatment
Treatment for first breast cancera CBC cases UBC controls
N (%) N (%) RRb (95 % CI) Overall P valued
Surgery alone 249 (16) 156 (7) 1.00 (Referent)
Chemotherapy alone 209 (14) 197 (9) 0.68 (0.49–0.93)
Tamoxifen alone 81 (5) 58 (3) 1.06 (0.69–1.64)
Radiotherapy alone 244 (16) 470 (21) 1.13 (0.88–1.47) <0.0001
Chemotherapy + tamoxifen 81 (5) 83 (4) 0.70 (0.47–1.05)
Chemotherapy + radiotherapy 319 (21) 569 (26) 0.82 (0.62–1.09)
Tamoxifen + radiotherapy 107 (7) 208 (9) 0.83 (0.60–1.16)
Chemotherapy + tamoxifen + radiotherapy 142 (9) 329 (15) 0.54 (0.39–0.76)
Other endocrine therapyc ± other treatment 89 (6) 141 (6) 0.49 (0.33–0.72)
One treatment or more unknown 0 (0) 1 (0.05)
aAll treatment categories include surgery
bAdjusted for all variables in the Table plus age at first breast cancer diagnosis (continuous), first-degree family history of breast cancer (yes, no, unknown), hist-
ology (lobular, other, unknown), stage (local, regional, unknown), and estrogen receptor/progesterone receptor status (positive for either, negative, unknown) at
first breast cancer diagnosis
cIncludes aromatase inhibitors (67 cases and 99 controls) and other anti-estrogens
dP value overall = 0.002 if the category “Radiotherapy alone” is removed from the model
CBC contralateral breast cancer, CI confidence interval, RR risk ratio, UBC unilateral breast cancer
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anthracycline or CMF regimens was found; however,
these analyses were not age-stratified [23]. In the
WECARE Study, we also observed little difference in CBC
risk by chemotherapy regimen, although the clearest risk
reduction was seen for CMF regimens.
The strengths of our study include the population-
based study design, the large sample size of women
diagnosed with CBC, and the detailed information on
treatment obtained from medical records. This enabled
us to adjust for other endocrine therapy including
aromatase-inhibitors that have been shown to be more
effective than tamoxifen in preventing CBC [24]. However,
some limitations exist. First, our study was not a random-
ized trial where treatment would be randomly assigned.
Also, women with breast cancer survived until recruit-
ment into the study, and we cannot exclude the possibility
that they may differ from otherwise eligible women who
were deceased. There was no reduction in CBC risk for
women using only tamoxifen and no other treatments;
however, this was a relatively small and distinct group. We
cannot rule out the possibility that a small fraction of
CBCs were actually metastases. However, we restricted
the underlying cohort of breast cancer patients to those
without distant spread at first diagnosis, and the sensitivity
analyses suggested that inclusion of participants with re-
currences before the CBC diagnosis did not substantially
affect our results.
Conclusion
In conclusion, the expanded WECARE data suggest that
treatment with tamoxifen or chemotherapy may offer
protection against a CBC for a limited period following
completion of treatment. Previously raised concerns that
tamoxifen may increase risk of ER-negative CBC could
not be substantiated.
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